{"@type": "dcat:Dataset", "accessLevel": "public", "accrualPeriodicity": "R/P1Y", "bureauCode": ["009:10"], "contactPoint": {"@type": "vcard:Contact", "fn": "Division of Drug Information", "hasEmail": "mailto:druginfo@fda.hhs.gov"}, "description": "Desvenlafaxine Succinate is a generic prescription medication available as extended-release oral tablets in 25 mg, 50 mg, and 100 mg strengths. It belongs to the class of serotonin and norepinephrine reuptake inhibitors, often used to treat major depressive disorder. Manufactured by Alembic Pharmaceuticals Limited and marketed by Direct Rx, it is approved under ANDA204003. This information was generated using AI and is provided for informational and research purposes only.", "distribution": [{"@type": "dcat:Distribution", "description": "\n        Access the FDA dataset for Desvenlafaxine succinate \u2014 ANDA 204003 submitted by Mylan Institutional LLC\n    ", "downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204003", "mediaType": "text/html", "title": "Desvenlafaxine succinate"}], "identifier": "ANDA204003", "issued": "2016-09-16", "keyword": ["drug", "drug-information", "drug-safety", "fda", "health-care"], "landingPage": "https://www.fda.gov/drugs", "license": "https://open.fda.gov/license", "modified": "2025-03-17", "programCode": ["009:002"], "publisher": {"@type": "org:Organization", "name": "U.S. Food and Drug Administration"}, "theme": ["FDA"], "title": "Desvenlafaxine succinate"}